• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OnKure Therapeutics Inc.

    3/10/25 4:31:17 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email
    S-8 1 okur_s-8_20250310_no_xbr.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 10, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ONKURE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    47-2309515

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    6707 Winchester Circle, Suite 400
    Boulder, Colorado 80301

    (Address of Principal Executive Offices, including zip code)

     

    OnKure Therapeutics, Inc. 2024 Equity Incentive Plan
    OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan

    (Full title of the plan)

    Nicholas A. Saccomano
    President and Chief Executive Officer
    6707 Winchester Circle, Suite 400

    Boulder, CO 80301

    (720) 307-2892

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

    Tony Jeffries

    Jennifer Knapp

    Phillip McGill

    Wilson Sonsini Goodrich & Rosati, P.C.

    1155 Canyon Blvd., Suite 400

    Boulder, CO 80302

    (303) 256-5900

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by OnKure Therapeutics, Inc. (the “Registrant”) for the purpose of registering (i) 667,355 additional shares of Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) of the Registrant reserved for issuance under the 2024 Equity Incentive Plan (the “2024 Plan”), pursuant to the provision of the 2024 Plan providing for an automatic increase in the number of shares reserved for issuance under the 2024 Plan, and (ii) 133,471 additional shares of Class A Common Stock of the Registrant reserved for issuance under the 2024 Employee Stock Purchase Plan (the “2024 ESPP”), pursuant to the provision of the 2024 ESPP providing for an automatic increase in the number of shares reserved for issuance under the 2024 ESPP.

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant previously registered shares of its Class A Common Stock for issuance under the 2024 Plan and the 2024 ESPP on a Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission on December 9, 2024 (File No. 333-283693) (the “Previous Form S-8”). Accordingly, pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the Previous Form S-8, including the information incorporated by reference therein and the periodic reports filed after the Previous Form S-8 to maintain current information about the Registrant, except as set forth below.

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

    1.
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025 (File No. 001-40315);
    2.
    All other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above, only to the extent that the items therein are specifically stated to be “filed” rather than “furnished” for the purposes of the Exchange Act; and
    3.
    The description of the Registrant’s Class A Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the SEC on April 6, 2021 pursuant to Section 12(b) of the Exchange Act, as updated by Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 10, 2025, including any amendment or report filed for the purpose of updating such description

    All other reports or documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents; provided, however, that reports, documents and information, or portions thereof, deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement

     

     


    contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits.

    The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

     

    EXHIBIT INDEX

    Exhibit
    Number

    Exhibit Description

    Incorporated by Reference

     

     

    Form

    File No.

    Exhibit

    Filing Date

    4.1

    Amended and Restated Certificate of Incorporation, as amended, of OnKure Therapeutics, Inc.

    8-K

    001-40315

    3.2

    October 8, 2024

    4.2

    Amended and Restated Bylaws of OnKure Therapeutics, Inc.

    8-K

    001-40315

    3.3

    October 8, 2024

    4.3

    2024 Equity Incentive Plan and forms of agreement thereunder.

    8-K

    001-40315

    10.14

    October 8, 2024

    4.4

    2024 Employee Stock Purchase Plan

    8-K

    001-40315

    10.15

    October 8, 2024

    5.1

    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.

    23.1

    Consent of KPMG LLP, independent registered public accounting firm.

    23.2

    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).

     

     

     

     

    24.1

    Power of Attorney (included on the signature page hereto).

    107

    Filing Fee Table

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 10, 2025.

    ONKURE THERAPEUTICS, INC.

     

     

    By:

    /s/ Nicholas A. Saccomano

     

    Nicholas A. Saccomano

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Nicholas A. Saccomano and Jason Leverone, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

    Signature

    Title

    Date

     

     

     

    /s/ Nicholas A. Saccomano

    Nicholas A. Saccomano

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

    March 10, 2025

     

     

     

    /s/ Jason Leverone

    Jason Leverone

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    March 10, 2025

     

     

     

    /s/ R. Michael Carruthers

    R. Michael Carruthers

    Director

    March 10, 2025

     

     

     

    /s/ Michael Grey

    Michael Grey

    Director

    March 10, 2025

     

     

     

    /s/ Valerie M. Jansen

    Valerie M. Jansen

    Director

    March 10, 2025

     

     

     

    /s/ Isaac Manke

    Isaac Manke

    Director

    March 10, 2025

     

     

     

     

    /s/ Edward T. Mathers

    Director

    March 10, 2025

    Edward T. Mathers

     

     

     

     

     

    /s/ Andrew Phillips

    Chairman

    March 10, 2025

    Andrew Phillips

     

     

     

     

     


     

     

     


    Get the next $OKUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

    -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provid

    11/6/25 4:03:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link. A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast

    11/4/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    -- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $83.4M expected to provide cash runway into Q4 2026 BOULDER, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutic

    8/12/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.

    SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    1/30/26 2:21:49 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/28/25 8:15:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by OnKure Therapeutics Inc.

    424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

    11/21/25 4:09:22 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Acorn Bioventures, L.P. bought $2,590,000 worth of shares (1,400,000 units at $1.85) (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    5/19/25 4:43:34 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mathers Edward T was granted 3,911 shares, increasing direct ownership by 34% to 15,310 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:16:56 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manke Isaac was granted 5,258 shares, increasing direct ownership by 34% to 20,583 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:10:23 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Saccomano Nicholas A sold $258 worth of shares (87 units at $2.97), decreasing direct ownership by 1% to 7,419 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    12/23/25 8:09:47 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on OnKure Therapeutics

    Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

    4/30/25 8:12:14 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

    Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

    12/5/24 8:06:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

    Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

    10/10/24 7:48:05 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Leadership Updates

    Live Leadership Updates

    View All

    OnKure Announces New Date for Upcoming Investor Call

    BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

    11/25/24 5:31:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Financials

    Live finance-specific insights

    View All

    OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

    -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

    12/10/24 7:00:00 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

    OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

    11/1/24 5:30:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 4:00:05 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OnKure Therapeutics Inc.

    SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 10:11:45 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    10/28/24 4:03:06 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care